IP Library Granted Patent US 11,965,004
Granted Patent B2
US 11,965,004 · App. 16/629,799 · Granted Apr 23, 2024

Molecular guide system peptides and uses thereof

Inventors: Kathlynn C. Brown (Staunton, VA); Nathan Collins (Menlo Park, CA); Shunzi “Susan” Li (Harrisonburg, VA); Curtis Allred (Menlo Park, CA); Keen Chung (Menlo Park, CA); Michael McGuire (Menlo Park, CA)
Assignee: SRI International
C07K14/4702A61K47/64A61P35/00C07K16/2803A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,965,004
App. No.
16/629,799
Granted
Apr 23, 2024
Kind
B2
Abstract

Disclosed are compositions comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides. Disclosed are methods of treating a subject in need thereof comprising administering to the subject in need thereof an effective amount of an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target involved in the disease process. Disclosed are methods of targeting an intracellular target comprising administering an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target.

Claims (13)

1. A composition comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides, directly or via a linker, wherein the one or more MGS peptides are selected from the group consisting of SEQ ID NOs: 2, 3, 20-22, and 38-41.

2. The composition of claim 1 , wherein the antibody targets an intracellular target.

3. The composition of claim 1 , wherein the antibody is a monoclonal antibody.

4. The composition of claim 3 , wherein the monoclonal antibody is an anti-Ras monoclonal antibody.

5. The composition of claim 1 , wherein the one or more MGS peptides consists of SEQ ID NO: 38.

6. The composition of claim 1 , wherein the one or more MGS peptides localize to an intracellular target selected from the lysosome, golgi apparatus, endoplasmic reticulum, cytoplasm, or nucleus.

7. The composition of claim 1 , wherein the antibody is conjugated to the one or more MGS peptides via a linker.

8. The composition of claim 7 , wherein the linker comprises polyethylene glycol (PEG).

9. A molecular guidance system (MGS) peptide selected from the group consisting of SEQ ID NOs: 2, 3, 20-22, and 38-41.

10. A method of targeting an intracellular target in a cell in vitro or in a subject, comprising contacting the cell with or administering to the subject a composition according to claim 1 , wherein the antibody targets an intracellular target.

11. The method of claim 10 , wherein the intracellular target is the lysosome, golgi apparatus, endoplasmic reticulum, cytoplasm, or nucleus.

12. A method of treating a subject having a disease in need thereof comprising administering to the subject in need thereof an effective amount of the composition of claim 1 , wherein the antibody targets an intracellular target involved in the disease process.

13. The method of claim 12 , wherein the subject in need thereof has an infectious disease, cancer, diabetes, a neurological or neurodegenerative disease, a genetically-inherited disease, or has been exposed to a bioterrorism agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2024
From: BROWN, KATHLYNN C.; COLLINS, NATHAN; LI, SHUNZI; ALLRED, CURTIS; CHUNG, KEEN; MCGUIRE, MICHAEL
To: SRI INTERNATIONAL
Reel/Frame 068109/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: BROWN, KATHLYNN C.; COLLINS, NATHAN; LI, SHUNZI "SUSAN"; ALLRED, CURTIS; CHUNG, KEEN; MCGUIRE, MICHAEL
To: SRI INTERNATIONAL
Reel/Frame 062314/0936 →
Continuity (2)
Provisional Application 62530633 · Jul 10, 2017
Related Publication 20220227823A1 · Jul 21, 2022
Cited By (2)
US 12,576,157 US 12,662,511